Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy
Xin Liu(University of Southern California), Rong‐Fu Wang(Houston Methodist), Zhiqiang An(Xiamen University), Yang Du(Fudan University), John S. Yu(Cedars-Sinai Medical Center), Changsheng Xing(University of Southern California), Yixiang Xu(Brown Foundation), Helen Y. Wang(University of Southern California), Wei Xiong(Houston Methodist), Tianhao Duan(University of Southern California), Ningyan Zhang(Brown Foundation), Yuqian Huang(Houston Methodist), Junjun Chu(Anhui University of Traditional Chinese Medicine), Bingnan Yin(University of Southern California), Qian Chen(The Affiliated Yongchuan Hospital of Chongqing Medical University)
Cited by 48
Related Papers
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma
|Molecular Cancer|2006|1.8k
Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity
|Frontiers in Immunology|2022|880
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
|Protein & Cell|2016|746
Impact of microbiota on central nervous system and neurological diseases: the gut-brain axis
|Journal of Neuroinflammation|2019|746